These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 38238671)
1. An immune-related exosome signature predicts the prognosis and immunotherapy response in ovarian cancer. Zhu K; Ma J; Tian Y; Liu Q; Zhang J BMC Womens Health; 2024 Jan; 24(1):49. PubMed ID: 38238671 [TBL] [Abstract][Full Text] [Related]
2. 5 signature genes revealed by single-cell profiling identified unique immune subtypes affecting the prognosis of ovarian cancer. Xiang SY; Li QK; Yang Z; Yi Q Eur Rev Med Pharmacol Sci; 2024 Mar; 28(5):2051-2062. PubMed ID: 38497886 [TBL] [Abstract][Full Text] [Related]
3. An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer. Cui Y; Zhang W; Lu W; Feng Y; Wu X; Zhuo Z; Zhang D; Zhang Y Front Immunol; 2024; 15():1228235. PubMed ID: 38404588 [TBL] [Abstract][Full Text] [Related]
4. Identification of an Autophagy-Related Signature for Prognosis and Immunotherapy Response Prediction in Ovarian Cancer. Ding J; Wang C; Sun Y; Guo J; Liu S; Cheng Z Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830707 [TBL] [Abstract][Full Text] [Related]
5. Integrative analysis of cuproptosis-associated genes for predicting immunotherapy response in single-cell and multi-cohort studies. Li H; Wang Y; Li G; Xiong J; Qin L; Wen Q; Yue C J Gene Med; 2024 Jan; 26(1):e3600. PubMed ID: 37776237 [TBL] [Abstract][Full Text] [Related]
6. Identification of STEAP3-based molecular subtype and risk model in ovarian cancer. Zhao Z; Sun C; Hou J; Yu P; Wei Y; Bai R; Yang P J Ovarian Res; 2023 Jun; 16(1):126. PubMed ID: 37386521 [TBL] [Abstract][Full Text] [Related]
7. A signature based on glycosyltransferase genes provides a promising tool for the prediction of prognosis and immunotherapy responsiveness in ovarian cancer. Xu X; Wu Y; Jia G; Zhu Q; Li D; Xie K J Ovarian Res; 2023 Jan; 16(1):5. PubMed ID: 36611197 [TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer subtypes based on the regulatory genes of RNA modifications: Novel prediction model of prognosis. Zheng P; Li N; Zhan X Front Endocrinol (Lausanne); 2022; 13():972341. PubMed ID: 36545327 [TBL] [Abstract][Full Text] [Related]
9. Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma. Chen L; Lin J; Wen Y; Chen Y; Chen CB Front Oncol; 2023; 13():1291720. PubMed ID: 38023241 [TBL] [Abstract][Full Text] [Related]
10. Construction of ovarian metastasis-related immune signature predicting prognosis of gastric cancer patients. Gao J; Huo S; Zhang Y; Zhao Z; Pan H; Liu X Cancer Med; 2023 Jan; 12(1):913-929. PubMed ID: 35621244 [TBL] [Abstract][Full Text] [Related]
11. Identification and validation of pyroptosis-related gene landscape in prognosis and immunotherapy of ovarian cancer. Gao L; Ying F; Cai J; Peng M; Xiao M; Sun S; Zeng Y; Xiong Z; Cai L; Gao R; Wang Z J Ovarian Res; 2023 Jan; 16(1):27. PubMed ID: 36707884 [TBL] [Abstract][Full Text] [Related]
12. Construction of an Immune Cell Infiltration Score to Evaluate the Prognosis and Therapeutic Efficacy of Ovarian Cancer Patients. Liu J; Wang Y; Yuan S; Wei J; Bai J Front Immunol; 2021; 12():751594. PubMed ID: 34745124 [TBL] [Abstract][Full Text] [Related]
13. Integration of scRNA-Seq and Bulk RNA-Seq to Analyse the Heterogeneity of Ovarian Cancer Immune Cells and Establish a Molecular Risk Model. Liang L; Yu J; Li J; Li N; Liu J; Xiu L; Zeng J; Wang T; Wu L Front Oncol; 2021; 11():711020. PubMed ID: 34621670 [TBL] [Abstract][Full Text] [Related]
14. CD4+ conventional T cells-related genes signature is a prognostic indicator for ovarian cancer. Hua T; Liu DX; Zhang XC; Li ST; Yan P; Zhao Q; Chen SB Front Immunol; 2023; 14():1151109. PubMed ID: 37063862 [TBL] [Abstract][Full Text] [Related]
15. Identifying the Role of Oxidative Stress-Related Genes as Prognostic Biomarkers and Predicting the Response of Immunotherapy and Chemotherapy in Ovarian Cancer. Liu Q; Yang X; Yin Y; Zhang H; Yin F; Guo P; Zhang X; Sun C; Li S; Han Y; Yang Z Oxid Med Cell Longev; 2022; 2022():6575534. PubMed ID: 36561981 [TBL] [Abstract][Full Text] [Related]
16. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer. Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G Front Genet; 2022; 13():919389. PubMed ID: 35783281 [No Abstract] [Full Text] [Related]
17. Investigating PPT2's role in ovarian cancer prognosis and immunotherapy outcomes. Xu H; Zhang Y; Xie Z; Xie XF; Qiao WL; Wang M; Zhao BB; Hua T J Ovarian Res; 2024 Oct; 17(1):198. PubMed ID: 39394143 [TBL] [Abstract][Full Text] [Related]
18. Contribution of m5C RNA Modification-Related Genes to Prognosis and Immunotherapy Prediction in Patients with Ovarian Cancer. Liu Y; Liu S; Yan L; Zhang Q; Liu W; Huang X; Liu S Mediators Inflamm; 2023; 2023():1400267. PubMed ID: 38022687 [TBL] [Abstract][Full Text] [Related]
19. Identification of copper metabolism-related subtypes and establishment of the prognostic model in ovarian cancer. Zhao S; Zhang X; Gao F; Chi H; Zhang J; Xia Z; Cheng C; Liu J Front Endocrinol (Lausanne); 2023; 14():1145797. PubMed ID: 36950684 [TBL] [Abstract][Full Text] [Related]
20. Exosome-Associated Gene Signature for Predicting the Prognosis of Ovarian Cancer Patients. Zhu Z; Geng R; Zhang Y; Liu J; Bai J J Immunol Res; 2023; 2023():8727884. PubMed ID: 36726489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]